Subscribe

Risk Factors for Cardiomyopathy in a Patient with Down's Syndrome Following Anthracycline Chemotherapy

Specialty:

Hematology Oncology
Cardiology
Clinical Pharmacology & Toxicology

Objective:

ICD-10:

Description:

A patient with Down's syndrome (Trisomy 21) is at greater risk for cardiomyopathy following chemotherapy with anthracyclines. Defects on chromosome 21 may affect activity of carbonyl reductase and superoxide dismutase which can result in enhanced toxicity of anthracycline metabolites.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone